Details of the Drug

General Information of Drug (ID: DMIKFEL)

Drug Name
Levomepromazine
Synonyms
METHOTRIMEPRAZINE; Nozinan; 60-99-1; Levoprome; Levomepromazina; Levomepromazinum; Levomepromazin; Nosinan; UNII-9G0LAW7ATQ; 2-Methoxytrimeprazine; Neozine; Levotomin; Minozinan; Milezin; 9G0LAW7ATQ; RP-7044; Levopromazioni; Veractil; Nomizan; Hirnamine; Dedoran; Nocinan; Nirnamine; CHEBI:6838; XP03; Methoxytrimeprazine; F-5116; Methotrimeprazine [USP]; Methotrimeprazine (USP); Bayer 1213; Arc-VI-C-5; CL 36467; CL 39743; Levomepromazinum [INN-Latin]; Levomepromazina [INN-Spanish]; EINECS 200-495-5; Methotrimeprazine
Indication
Disease Entry ICD 11 Status REF
Bipolar disorder 6A60 Approved [1], [2]
Psychotic disorder 6A20-6A25 Approved [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 328.5
Topological Polar Surface Area (xlogp) 4.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 9.9 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [3]
Metabolism
The drug is metabolized via the hepatic [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 12 L/kg [3]
Chemical Identifiers
Formula
C19H24N2OS
IUPAC Name
(2R)-3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
Canonical SMILES
C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C
InChI
InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
InChIKey
VRQVVMDWGGWHTJ-CQSZACIVSA-N
Cross-matching ID
PubChem CID
72287
ChEBI ID
CHEBI:6838
CAS Number
60-99-1
DrugBank ID
DB01403
TTD ID
D09LZT
VARIDT ID
DR01271
INTEDE ID
DR0942

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Bipolar disorder
ICD Disease Classification 6A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Levomepromazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Levomepromazine and Ivosidenib. Acute myeloid leukaemia [2A60] [35]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Midostaurin. Acute myeloid leukaemia [2A60] [36]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Arn-509. Acute myeloid leukaemia [2A60] [37]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Gilteritinib. Acute myeloid leukaemia [2A60] [38]
Oliceridine DM6MDCF Major Decreased metabolism of Levomepromazine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [39]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Levomepromazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [40]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Levomepromazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [40]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Levomepromazine and Ivabradine. Angina pectoris [BA40] [37]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Levomepromazine and Dronedarone. Angina pectoris [BA40] [36]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Levomepromazine and Amyl nitrite. Angina pectoris [BA40] [41]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Levomepromazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Levalbuterol. Asthma [CA23] [43]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Retigabine. Behcet disease [4A62] [44]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Levomepromazine and Cariprazine. Bipolar disorder [6A60] [45]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Eribulin. Breast cancer [2C60-2C6Y] [36]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Levomepromazine when combined with Acetylcholine. Cataract [9B10] [46]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [47]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Levomepromazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [48]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Levomepromazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [49]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [43]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Levomepromazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [48]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Levomepromazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [48]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [49]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Levomepromazine and Pasireotide. Cushing syndrome [5A70] [36]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Osilodrostat. Cushing syndrome [5A70] [35]
OPC-34712 DMHG57U Major Decreased metabolism of Levomepromazine caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [50]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Levomepromazine and Esketamine. Depression [6A70-6A7Z] [51]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Levomepromazine and Mepenzolate. Digestive system disease [DE2Z] [40]
Tetrabenazine DMYWQ0O Major Decreased metabolism of Levomepromazine caused by Tetrabenazine mediated inhibition of CYP450 enzyme. Dissociative neurological symptom disorder [6B60] [52]
Deutetrabenazine DMUPFLI Major Decreased metabolism of Levomepromazine caused by Deutetrabenazine mediated inhibition of CYP450 enzyme. Dystonic disorder [8A02] [53]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Levomepromazine and Ingrezza. Dystonic disorder [8A02] [54]
Stiripentol DMMSDOY Moderate Decreased metabolism of Levomepromazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Solifenacin. Functional bladder disorder [GC50] [36]
Mirabegron DMS1GYT Moderate Decreased metabolism of Levomepromazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [56]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [57]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Levomepromazine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [36]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Levomepromazine and Nebivolol. Hypertension [BA00-BA04] [41]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Levomepromazine and Levamlodipine. Hypertension [BA00-BA04] [41]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Levomepromazine and TAK-491. Hypertension [BA00-BA04] [41]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Levomepromazine and Clevidipine butyrate. Hypertension [BA00-BA04] [41]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Levomepromazine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [37]
Givosiran DM5PFIJ Moderate Decreased metabolism of Levomepromazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [59]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Levomepromazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [45]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Levomepromazine and ITI-007. Insomnia [7A00-7A0Z] [45]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Levomepromazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [36]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Levomepromazine caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [60]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Levomepromazine and Crizotinib. Lung cancer [2C25] [61]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Levomepromazine and Ceritinib. Lung cancer [2C25] [36]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Levomepromazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [62]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Levomepromazine and Osimertinib. Lung cancer [2C25] [63]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Levomepromazine and Selpercatinib. Lung cancer [2C25] [64]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Levomepromazine and Lumefantrine. Malaria [1F40-1F45] [51]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Levomepromazine and Hydroxychloroquine. Malaria [1F40-1F45] [65]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [37]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Levomepromazine and Vemurafenib. Melanoma [2C30] [36]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and LGX818. Melanoma [2C30] [66]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Levomepromazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [67]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Levomepromazine and Lasmiditan. Migraine [8A80] [68]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Levomepromazine and Flibanserin. Mood disorder [6A60-6E23] [69]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Levomepromazine and Panobinostat. Multiple myeloma [2A83] [70]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Levomepromazine and Siponimod. Multiple sclerosis [8A40] [51]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Levomepromazine and Fingolimod. Multiple sclerosis [8A40] [36]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Levomepromazine and Ozanimod. Multiple sclerosis [8A40] [71]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Romidepsin. Mycosis fungoides [2B01] [44]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Levomepromazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Levomepromazine and Nilotinib. Myeloproliferative neoplasm [2A20] [36]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Levomepromazine when combined with Dextroamphetamine. Narcolepsy [7A20] [72]
Rolapitant DM8XP26 Moderate Decreased metabolism of Levomepromazine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [73]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Entrectinib. Non-small cell lung cancer [2C25] [37]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Levomepromazine when combined with Phendimetrazine. Obesity [5B80-5B81] [72]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Levomepromazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [74]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Levomepromazine and Lofexidine. Opioid use disorder [6C43] [36]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Rucaparib. Ovarian cancer [2C73] [36]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Levomepromazine when combined with Methamphetamine. Pain [MG30-MG3Z] [75]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Triclabendazole. Parasitic worm infestation [1F90] [44]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Levomepromazine and Safinamide. Parkinsonism [8A00] [76]
Opicapone DM1BKA6 Moderate Antagonize the effect of Levomepromazine when combined with Opicapone. Parkinsonism [8A00] [77]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Pimavanserin. Parkinsonism [8A00] [78]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Levomepromazine and Methylscopolamine. Peptic ulcer [DA61] [45]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Levomepromazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [79]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Levomepromazine and Lefamulin. Pneumonia [CA40] [35]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Degarelix. Prostate cancer [2C82] [37]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Levomepromazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [80]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Enzalutamide. Prostate cancer [2C82] [37]
Neupro DMHEAB1 Moderate Antagonize the effect of Levomepromazine when combined with Neupro. Restless legs syndrome [7A80] [81]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Levomepromazine and Iloperidone. Schizophrenia [6A20] [36]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Levomepromazine and Molindone. Schizophrenia [6A20] [45]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Levomepromazine and Thiothixene. Schizophrenia [6A20] [45]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Levomepromazine and Amisulpride. Schizophrenia [6A20] [82]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Asenapine. Schizophrenia [6A20] [36]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Levomepromazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [36]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Levomepromazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [36]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [37]
Pitolisant DM8RFNJ Major Decreased metabolism of Levomepromazine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [37]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [36]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Levomepromazine and Lenvatinib. Thyroid cancer [2D10] [36]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Levomepromazine and Cabozantinib. Thyroid cancer [2D10] [37]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Levomepromazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [40]
⏷ Show the Full List of 99 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7603).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
7 Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
8 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
9 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
10 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
11 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
14 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
15 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
16 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
17 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
18 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
19 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
20 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
21 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
22 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
23 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
24 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
25 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
26 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
27 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
28 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
29 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
31 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
32 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
33 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
34 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
35 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
36 Canadian Pharmacists Association.
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
39 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
40 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
41 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
42 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
43 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
45 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
46 Multum Information Services, Inc. Expert Review Panel.
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
49 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
50 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
51 Cerner Multum, Inc. "Australian Product Information.".
52 Product Information. Xenazine (tetrabenazine). Prestwick Pharmaceuticals Inc, Washington DC, VA.
53 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
54 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
55 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
56 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
57 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
58 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
59 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
60 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
61 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
64 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
65 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
66 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
67 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
68 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
69 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
70 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
71 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
72 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
73 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
74 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
75 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
76 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
77 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
78 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
79 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
80 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
81 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
82 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.